New developments in immunotherapy for lymphoma
The development of immunotherapies for lymphoma has undergone a revolutionary evolution over the past decades. Since the advent of rituximab as the first successful immunotherapy for B-cell non-Hodgkin lymphoma over two decades ago, a plethora of new immunotherapeutic approaches to treat lymphoma ha...
Main Authors: | Benjamin Heyman, Yiping Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2018-09-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/1176 |
Similar Items
-
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
by: Jaco A. C. van Bruggen, et al.
Published: (2020-12-01) -
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
by: Robert Pytlik, et al.
Published: (2020-11-01) -
Cancer Immunotherapy and the Immune Response in Follicular Lymphoma
by: Frank Stenner, et al.
Published: (2018-06-01) -
Recent developments in immunotherapy of acute myeloid leukemia
by: Felix S. Lichtenegger, et al.
Published: (2017-07-01) -
Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
by: Li Li, et al.
Published: (2021-01-01)